Aihe Zhou

USPTO Granted Patents = 14 (Patent Applications = 12)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 13.2

ph-index = 5

Forward Citations = 90(Granted Patents)

Location History:

South San Francisco, CA (US) (2014 - 2019)
San Jose, CA (US) (2002 - 2023)

Company Filing History:

F. Hoffmann-la Roche Ag

Hoffman-laroche, Inc. (us Only)

patent

6. 1 out of 1

F. Hoffman-laroche, Ag (ex-us)

patent

where one patent can have more than one assignee

Years Active: 2002-2023

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

2. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

3. 10519126 - Serine/threonine kinase inhibitors (2019-12-31),

4. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),

5. 9708290 - Serine/threonine kinase inhibitors (2017-07-18),

6. 9388171 - Serine/threonine kinase inhibitors (2016-07-12),

7. 9259470 - Serine/threonine kinase inhibitors (2016-02-16),

8. 8999998 - Pyrazolopyrimidine JAK inhibitor compounds and methods (2015-04-07),

9. 8697715 - Serine/threonine kinase inhibitors (2014-04-15),

10. 8637526 - Pyrazolopyrimidine JAK inhibitor compounds and methods (2014-01-28),

11. 8486950 - Janus kinase inhibitor compounds and methods (2013-07-16),

12. 7749994 - Pentacyclic kinase inhibitors (2010-07-06),

13. 6919369 - Serine protease inhibitors (2005-07-19),

14. 6472393 - Serine protease inhibitors (2002-10-29),

Title: The Innovation Journey of Aihe Zhou: Pioneering Patents in San Jose

Introduction:

Aihe Zhou, a prolific inventor based in San Jose, CA, has made significant contributions to the field of biopharmaceuticals with his groundbreaking patented inventions. With 14 patents to his name, Zhou's work has focused on developing novel compounds for treating HPK1-dependent disorders and enhancing immune responses.

Latest Patents:

Zhou's latest patents include Isoquinolines and Naphthyridines as inhibitors of HPK1, showcasing his innovative approach to addressing critical medical needs. These compounds hold promise in the treatment of HPK1-dependent disorders and the stimulation of immune responses, offering new avenues for therapeutic intervention.

Career Highlights:

Throughout his career, Zhou has been associated with prestigious companies such as Genentech, Inc., and Array Biopharma Inc., where he has honed his expertise in drug discovery and development. His multidisciplinary background has been instrumental in his success as an inventor in the biopharmaceutical industry.

Collaborations:

Zhou has collaborated with esteemed professionals in the field, including Kirk D Robarge and Mark Joseph Chicarelli, further enriching his innovative endeavors. Together, they have pushed the boundaries of biopharmaceutical research, working towards improving patient outcomes and advancing medical science.

Conclusion:

Aihe Zhou's exceptional work in inventing novel compounds for addressing HPK1-dependent disorders exemplifies his commitment to innovation and improving healthcare outcomes. His patents stand as a testament to his ingenuity and dedication to advancing the field of biopharmaceuticals, leaving a lasting impact on the industry and patients worldwide.

This text is generated by artificial intelligence and may not be accurate.